144 related articles for article (PubMed ID: 34297363)
1. Effects of prebiotics on postprandial GLP-1, GLP-2 and glucose regulation in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled crossover trial.
Birkeland E; Gharagozlian S; Gulseth HL; Birkeland KI; Hartmann B; Holst JJ; Holst R; Aas AM
Diabet Med; 2021 Oct; 38(10):e14657. PubMed ID: 34297363
[TBL] [Abstract][Full Text] [Related]
2. Effect of inulin-type fructans on appetite in patients with type 2 diabetes: a randomised controlled crossover trial.
Birkeland E; Gharagozlian S; Birkeland KI; Holm OKS; Thorsby PM; Aas AM
J Nutr Sci; 2021; 10():e72. PubMed ID: 34589204
[TBL] [Abstract][Full Text] [Related]
3. Effects of prebiotic inulin-type fructans on blood metabolite and hormone concentrations and faecal microbiota and metabolites in overweight dogs.
Alexander C; Cross TL; Devendran S; Neumer F; Theis S; Ridlon JM; Suchodolski JS; de Godoy MRC; Swanson KS
Br J Nutr; 2018 Sep; 120(6):711-720. PubMed ID: 30064535
[TBL] [Abstract][Full Text] [Related]
4. Prebiotic effect of inulin-type fructans on faecal microbiota and short-chain fatty acids in type 2 diabetes: a randomised controlled trial.
Birkeland E; Gharagozlian S; Birkeland KI; Valeur J; Måge I; Rud I; Aas AM
Eur J Nutr; 2020 Oct; 59(7):3325-3338. PubMed ID: 32440730
[TBL] [Abstract][Full Text] [Related]
5. Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes.
Dalsgaard NB; Gasbjerg LS; Helsted MM; Hansen LS; Hansen NL; Skov-Jeppesen K; Hartmann B; Holst JJ; Vilsbøll T; Knop FK
Bone; 2023 May; 170():116687. PubMed ID: 36754130
[TBL] [Abstract][Full Text] [Related]
6. The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial.
Juel CTB; Lund A; Andersen MM; Hansen CP; Storkholm JH; Rehfeld JF; van Hall G; Hartmann B; Wewer Albrechtsen NJ; Holst JJ; Vilsbøll T; Knop FK
Diabetologia; 2020 Jul; 63(7):1285-1298. PubMed ID: 32394228
[TBL] [Abstract][Full Text] [Related]
7. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
9. The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes.
Dalsgaard NB; Gasbjerg LS; Hansen LS; Hansen NL; Stensen S; Hartmann B; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Eur J Endocrinol; 2021 Mar; 184(3):383-394. PubMed ID: 33449919
[TBL] [Abstract][Full Text] [Related]
10. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Flint A; Kapitza C; Hindsberger C; Zdravkovic M
Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
[TBL] [Abstract][Full Text] [Related]
11. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
12. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
13. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
Højberg PV; Vilsbøll T; Zander M; Knop FK; Krarup T; Vølund A; Holst JJ; Madsbad S
Diabet Med; 2008 Nov; 25(11):1268-75. PubMed ID: 19046215
[TBL] [Abstract][Full Text] [Related]
14. Replacement of glycaemic carbohydrates by inulin-type fructans from chicory (oligofructose, inulin) reduces the postprandial blood glucose and insulin response to foods: report of two double-blind, randomized, controlled trials.
Lightowler H; Thondre S; Holz A; Theis S
Eur J Nutr; 2018 Apr; 57(3):1259-1268. PubMed ID: 28255654
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.
Gutniak MK; Larsson H; Sanders SW; Juneskans O; Holst JJ; Ahrén B
Diabetes Care; 1997 Dec; 20(12):1874-9. PubMed ID: 9405910
[TBL] [Abstract][Full Text] [Related]
16. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
[TBL] [Abstract][Full Text] [Related]
17. Effect of prebiotic intake on gut microbiota, intestinal permeability and glycemic control in children with type 1 diabetes: study protocol for a randomized controlled trial.
Ho J; Reimer RA; Doulla M; Huang C
Trials; 2016 Jul; 17(1):347. PubMed ID: 27456494
[TBL] [Abstract][Full Text] [Related]
18. Effect of meal composition on postprandial glucagon-like peptide-1, insulin, glucagon, C-peptide, and glucose responses in overweight/obese subjects.
Shah M; Franklin B; Adams-Huet B; Mitchell J; Bouza B; Dart L; Phillips M
Eur J Nutr; 2017 Apr; 56(3):1053-1062. PubMed ID: 26759261
[TBL] [Abstract][Full Text] [Related]
19. Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients.
Sonne DP; Hare KJ; Martens P; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(4):G413-9. PubMed ID: 23275610
[TBL] [Abstract][Full Text] [Related]
20. Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans.
Melhorn SJ; Tyagi V; Smeraglio A; Roth CL; Schur EA
Appetite; 2014 Nov; 82():85-90. PubMed ID: 25049134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
